Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech

Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.

Finance Watch

The Biotechnology Innovation Organization (BIO) has submitted comments to the US Department of the Treasury about proposed foreign investment regulations that the trade group believes will prevent foreign investors from putting capital into US biotech firms, which have grown increasingly dependent on ex-US investors.

BIO’s comments submitted 18 October focus primarily on definitions of “sensitive personal data,” “genetic information” and “identifiable data,” since the proposed regulations require scrutiny of foreign investments in companies dealing with sensitive personal data and genetic information by the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business